These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 2673831)

  • 1. Progenitor cell numbers (CFU-GM, CFU-D, and CFU-Mix) and hemopoietic recovery following autologous marrow transplantation.
    Stewart FM; Kaiser DL; Ishitani KP; Pirsch GW; Niskanen E
    Exp Hematol; 1989 Oct; 17(9):974-80. PubMed ID: 2673831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
    Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations in both the hematopoietic microenvironment and the progenitor cell population follow the recovery from myeloablative therapy and bone marrow transplantation.
    Novitzky N; Mohamed R
    Exp Hematol; 1995 Dec; 23(14):1661-6. PubMed ID: 8542962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engraftment with peripheral blood stem cells using noncontrolled-rate cryopreservation: comparison with autologous bone marrow transplantation.
    Rosenfeld CS; Gremba C; Shadduck RK; Zeigler ZR; Nemunaitis J
    Exp Hematol; 1994 Mar; 22(3):290-4. PubMed ID: 7509292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recovery of CFU-GM from cryopreserved marrow and in vivo evaluation after autologous bone marrow transplantation are predictive of engraftment.
    Douay L; Gorin NC; Mary JY; Lemarie E; Lopez M; Najman A; Stachowiak J; Giarratana MC; Baillou C; Salmon C
    Exp Hematol; 1986 Jun; 14(5):358-65. PubMed ID: 3519263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants.
    To LB; Roberts MM; Haylock DN; Dyson PG; Branford AL; Thorp D; Ho JQ; Dart GW; Horvath N; Davy ML
    Bone Marrow Transplant; 1992 Apr; 9(4):277-84. PubMed ID: 1350938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term engraftment failure after marrow ablation and autologous hematopoietic reconstitution: differences between peripheral blood stem cell and bone marrow recipients.
    Bentley SA; Brecher ME; Powell E; Serody JS; Wiley JM; Shea TC
    Bone Marrow Transplant; 1997 Mar; 19(6):557-63. PubMed ID: 9085735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral blood progenitor cell transplantation: a single centre experience comparing two mobilisation regimens in 67 patients.
    Mahendra P; Johnson D; Scott MA; Jestice HK; Hood IM; Ager S; Bass G; Barker P; Boraks PA; Bloxham DM; Baglin TP; Marcus RE
    Bone Marrow Transplant; 1996 Apr; 17(4):503-7. PubMed ID: 8722346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Favorable effect of hematopoietic stem cells isolated from blood on hematologic recovery following high-dosage chemotherapy].
    Richel DJ; Baars JW; Wijngaarden MJ; van der Schoot CE; Vlasveld LT; Rodenhuis S
    Ned Tijdschr Geneeskd; 1993 Jan; 137(5):245-50. PubMed ID: 7679478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Difference in kinetics of hematopoietic reconstitution between ALL and ANLL after autologous bone marrow transplantation with marrow treated in vitro with mafosfamide (ASTA Z 7557).
    Douay L; Laporte JP; Mary JY; Lopez M; Lemonnier MP; Stachowiak J; Benitez O; Deloux J; Najman A; Salmon C
    Bone Marrow Transplant; 1987 Jun; 2(1):33-43. PubMed ID: 3332155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship of infused CFU-GM and CFU-Mk mobilized by chemotherapy with or without G-CSF to platelet recovery after autologous blood stem cell transplantation.
    Takamatsu Y; Harada M; Teshima T; Makino S; Inaba S; Akashi K; Shibuya T; Niho Y
    Exp Hematol; 1995 Jan; 23(1):8-13. PubMed ID: 7527786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors influencing hematopoietic recovery after autologous blood stem cell transplantation in patients with acute myeloblastic leukemia and with non-myeloid malignancies.
    Carral A; de la Rubia J; Martín G; Martínez J; Sanz G; Jarque I; Sempere A; Soler MA; Marty ML; Sanz MA
    Bone Marrow Transplant; 2002 May; 29(10):825-32. PubMed ID: 12058232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CFU-GEMM correlate with neutrophil and platelet recovery in patients receiving autologous marrow transplantation after high-dose melphalan chemotherapy.
    Roodman GD; LeMaistre CF; Clark GM; Page CP; Newcomb TF; Knight WA
    Bone Marrow Transplant; 1987 Aug; 2(2):165-73. PubMed ID: 3332164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors influencing haemopoietic recovery following chemotherapy-mobilised autologous peripheral blood progenitor cell transplantation for haematological malignancies: a retrospective analysis of a 10-year single institution experience.
    Lowenthal RM; Fabères C; Marit G; Boiron JM; Cony-Makhoul P; Pigneux A; Agape P; Vezon G; Bouzgarou R; Dazey B; Fizet D; Bernard P; Lacombe F; Reiffers J
    Bone Marrow Transplant; 1998 Oct; 22(8):763-70. PubMed ID: 9827973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of factors predicting speed of hematologic recovery after transplantation with 4-hydroperoxycyclophosphamide-purged autologous bone marrow grafts.
    Rowley SD; Piantadosi S; Marcellus DC; Jones RJ; Davidson NE; Davis JM; Kennedy J; Wiley JM; Wingard JR; Yeager AM
    Bone Marrow Transplant; 1991 Mar; 7(3):183-91. PubMed ID: 2059755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of progenitor cell dose and preleukapheresis use of human recombinant granulocyte colony-stimulating factor on the recovery of hematopoiesis after blood stem cell autografting in children.
    Kawano Y; Takaue Y; Watanabe T; Saito S; Abe T; Hirao A; Sato J; Ninomiya T; Suzue T; Koyama T
    Exp Hematol; 1993 Jan; 21(1):103-8. PubMed ID: 7678082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Failure of bone marrow cryopreservation in chronic granulocytic leukemia: relation to excessive granulo-macrophagic progenitor pool.
    Douay L; Lopez M; Gorin NC; Nauman A; Giarratana MC; Laporte JP; Stachowiak J; Salmon C; Duhamel G
    Int J Cell Cloning; 1986 Jul; 4(4):250-62. PubMed ID: 2875118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF.
    Hohaus S; Goldschmidt H; Ehrhardt R; Haas R
    Exp Hematol; 1993 Apr; 21(4):508-14. PubMed ID: 7681782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hematopoietic stem cell deficit of transplanted bone marrow previously exposed to cytotoxic agents.
    Neben S; Hellman S; Montgomery M; Ferrara J; Mauch P
    Exp Hematol; 1993 Jan; 21(1):156-62. PubMed ID: 8435103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A mononuclear cell dose of 3 x 10(8)/kg predicts early multilineage recovery in patients with malignant lymphoma treated with carmustine, etoposide, Ara-C and melphalan (BEAM) and peripheral blood progenitor cell transplantation.
    Smith RJ; Sweetenham JW
    Exp Hematol; 1995 Dec; 23(14):1581-8. PubMed ID: 8542950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.